XML 96 R79.htm IDEA: XBRL DOCUMENT v3.22.1

Long-Term Investments (Details) - Schedule of long-term investment - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Non-marketable Cost Method Investments, net
Sub total	$ 904,254	$ 932,755	$ 922,391
Equity Method Investments, net
Total	904,254	932,755	1,190,727
Braingenesis Biotechnology Co., Ltd. [Member]
Non-marketable Cost Method Investments, net
Sub total	7,698	7,941	7,853
Genepharm Biotech Corporation [Member]
Non-marketable Cost Method Investments, net
Sub total	23,503	24,244	23,974
BioHopeKing Corporation [Member]
Non-marketable Cost Method Investments, net
Sub total	873,053	900,570	890,564
BioFirst Corporation [Member]
Equity Method Investments, net
Total			268,336
Rgene Corporation [Member]
Equity Method Investments, net
Total

X

- References

No definition available.

+ Details

Name:	abvc_EquityMethodInvestmentsNetAbstract0
Namespace Prefix:	abvc_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	abvc_NonMarketableCostMethodInvestmentsNetAbstract0
Namespace Prefix:	abvc_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	abvc_NonmarketableCostMethodInvestmentsNet
Namespace Prefix:	abvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(10))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599

+ Details

Name:	us-gaap_EquityMethodInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvc_BraingenesisBiotechnologyCoLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvc_GenepharmBiotechCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: